SCHEMBL4626091

SCHEMBL4626091

CC(C)(C)O[Si](Oc1ccc(Br)cc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPK1 P28482 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
TSHR P16473 1/20 0.32
SLC6A4 P31645 2/20 0.31
ABCG2 Q9UNQ0 1/20 0.31
ACP1 P24666 1/20 0.31
LMNA P02545 1/20 0.31
PKM P14618 1/20 0.31
KMT2A Q03164 1/20 0.31
SLC6A2 P23975 1/20 0.30
SLC6A3 Q01959 1/20 0.30
CES2 O00748 1/20 0.30
CES1 P23141 1/20 0.30
RECQL P46063 1/20 0.30
MAPT P10636 1/20 0.30
MCL1 Q07820 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4625644 0.81 NR1H2 (0.35) ALDH1A1TDP1KMT2AMAPT
SCHEMBL4625906 0.80 CYP19A1 (0.37) ALDH1A1TDP1KMT2AMAPT
SCHEMBL4625876 0.80 ELANE (0.49)
SCHEMBL4625813 0.80 CYP19A1 (0.37) ALDH1A1TDP1KMT2AMAPT
SCHEMBL6058734 0.79 ALDH1A1 (0.37) ALDH1A1KDM4EMAPK1TDP1TSHR
SCHEMBL4627743 0.78 ELANE (0.51) ALDH1A1TDP1TSHR
SCHEMBL430199 0.78 MAPK1 (0.37) ALDH1A1MAPK1TDP1TSHRSLC6A2
SCHEMBL4626920 0.76 AHR (0.43) ALDH1A1LMNAKMT2ACES2CES1
SCHEMBL4624707 0.76 AHR (0.43) ALDH1A1LMNAKMT2ACES2CES1
SCHEMBL703604 0.76 ESR1 (0.37) ALDH1A1MAPK1TDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1401851-B8 TWO-STAGE PROTECTIVE GROUPS FOR THE SYNTHESIS OF BIOPOLYMERS FEBIT HOLDING GMBH (DE) 2008-09-10 EP disclosed
EP-1401851-B1 TWO-STAGE PROTECTIVE GROUPS FOR THE SYNTHESIS OF BIOPOLYMERS FEBIT BIOTECH GMBH (DE) 2008-07-02 EP disclosed
US-7355036-B2 Two-stage protective groups for the synthesis of biopolymers FEBIT AG (DE) 2008-04-08 US disclosed
US-20040197851-A1 Two-stage protective groups for the synthesis of biopolymers MR. CHRISTOPHER SEAGON, ESQ. (DE) 2004-10-07 US disclosed
EP-1401851-A1 TWO-STAGE PROTECTIVE GROUPS FOR THE SYNTHESIS OF BIOPOLYMERS Febit AG (DE) 2004-03-31 EP disclosed
WO-2003004510-A1 TWO-STAGE PROTECTIVE GROUPS FOR THE SYNTHESIS OF BIOPOLYMERS FEBIT AG (DE) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040197851-A1 Two-stage protective groups for the synthesis of biopolymers CTRB2, OGG1, CPB2 ALDH1A1 1433/4885KDM4E 3608/4885MAPK1 4411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.